New HIV drugs set to be cheaper

Patients will save thousands of dollars with PBS listing of two-drug regimen
saving money

A new single-dose, two-drug regimen to treat HIV, dolutegravir and rilpivirine, is to be listed on the PBS.

The 1 December listing will substantially reduce the cost of the drugs for patients, which currently retail at $10,800 a year.

The step comes as the Federal Government launches Australia's eighth national HIV strategy, which aims to virtually eliminate transmission of the virus by 2022.

The TGA approved the once-daily dolutegravir and rilpivirine (Juluca) as a treatment for HIV in July.